Neumora Therapeutics(US:NMRA) Prnewswire·2025-03-01 15:02Core Points - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. on behalf of investors who purchased its common stock during its initial public offering around September 15, 2023 [1] - The lead plaintiff deadline for the lawsuit is set for April 7, 2025 [1] Allegations Against Defendants - The complaint alleges that Neumora made materially false and misleading statements in its Offering Documents, including the need to amend Phase Two Trial inclusion criteria to justify its Phase Three Program [2] - It is claimed that Neumora added a prespecified analysis to the Phase Two statistical analysis plan focusing on patients with moderate to severe major depressive disorder [2] - The Phase Two Trials reportedly lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2] Lead Plaintiff Process - Investors in Neumora can seek to be appointed as a lead plaintiff representative of the class by April 7, 2025, or may choose to remain absent [3] - The lead plaintiff acts on behalf of all class members and selects counsel to represent the class [3] - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3] Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm encourages Neumora investors who have suffered losses to contact them for more information [4]